![](/client/images/blank.gif)
Eylem Seç
![Trends in the Off-label Use of Histrelin Acetate Implants in Transgender Children için kapak resmi Trends in the Off-label Use of Histrelin Acetate Implants in Transgender Children için kapak resmi](/client/assets/d79c3e4af2b6d196/ctx/images/no_image.png)
Trends in the Off-label Use of Histrelin Acetate Implants in Transgender Children
Başlık:
Trends in the Off-label Use of Histrelin Acetate Implants in Transgender Children
Yazar:
Lopez, Carla Marisa, author.
ISBN:
9780438131989
Yazar Ek Girişi:
Fiziksel Tanımlama:
1 electronic resource (37 pages)
Genel Not:
Source: Dissertation Abstracts International, Volume: 79-11(E), Section: B.
Advisors: Emily R. Christison-Lagay.
Özet:
The goal of this study was to identify national trends in the utilization of histrelin acetate (Supprelin) implants among transgender children in the United States. We analyzed demographic, diagnostic, and treatment data from 2004 to 2016 on the use of histrelin acetate reported to the Pediatric Health Information System (PHIS) to determine the temporal trends in its use for transgender-related billing diagnoses, e.g. "Gender Identity Disorder." Demographic and payer status data on this patient population was also collected.
Between 2004 and 2016, the annual number of implants placed for a transgender related diagnosis increased from 0 to 63. The average age for placement was 14 years. Compared to natal females, natal males were more likely to receive implants (57 versus 46) and more likely to have implants placed at an older age (62% of natal males versus 50% of natal females were ≥13 years; p<0.04). The majority of children were white non-Hispanic (white: 60, minority: 21). When compared to the distribution of patients treated for precocious puberty (white: 1428, minority: 1421), white non-Hispanic patients were more likely to be treated with a histrelin acetate implant for a transgender related diagnosis than minority patients (p<0.001). This disparity was present even among minority patients with commercial insurance (p<0.001).
Utilization of histrelin acetate implants among transgender children has increased dramatically. Compared to natal females, natal males are more likely to receive implants and also more likely to receive implants at an older age. Treated transgender patients are more likely to be white when compared to the larger cohort of patients being treated with histrelin acetate for central precocious puberty (CPP), thus identifying a potential racial disparity in access to medically appropriate transgender care.
Notlar:
School code: 0265
Konu Başlığı:
Tüzel Kişi Ek Girişi:
Mevcut:*
Yer Numarası | Demirbaş Numarası | Shelf Location | Lokasyon / Statüsü / İade Tarihi |
---|---|---|---|
XX(688291.1) | 688291-1001 | Proquest E-Tez Koleksiyonu | Arıyor... |
On Order
Liste seç
Bunu varsayılan liste yap.
Öğeler başarıyla eklendi
Öğeler eklenirken hata oldu. Lütfen tekrar deneyiniz.
:
Select An Item
Data usage warning: You will receive one text message for each title you selected.
Standard text messaging rates apply.